BRAF Kinase Inhibitors Market

BRAF Kinase Inhibitors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

BRAF Kinase Inhibitors Market Introduction

BRAF is a human gene that encodes the BRAF protein. The BRAF protein is more formally known as serine/threonine-protein kinase BRAF. The BRAF gene is also known as VRAF murine sarcoma viral oncogene homolog B and proto-oncogene BRAF. BRAF is a member of the RAF kinase family of growth signal transduction protein kinases. These proteins play an important role in regulating the MAP kinase signaling pathway. The signaling pathway affects cell differentiation, division, and secretion. Mutation in BRAF proteins can cause certain types of cancer including colorectal cancer and melanoma. Blocking mutated BRAF kinase proteins can help in inhibition of growth of cancerous cells. Hence, certain types of BRAF kinase inhibitors are used to treat a few types of cancer. BRAF kinase inhibitors are used as targeted therapy drugs for the treatment of non-small-cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), and melanomas caused by mutations of the BRAF gene. These drugs directly target the BRAF protein and inhibit the growth of cancerous cells in patients with metastatic melanoma.

BRAF Kinase Inhibitors Market – Competitive Landscape

The global BRAF Kinase inhibitors market is consolidated with very few global players accounting for major market share in international market. Leading biopharmaceutical companies have made significant investments in clinical research studies in to address the untapped market. In June 2017, the Food and Drug Administration (FDA) approved Dabrafenib and Trametinib regimen for the treatment of a rare subset of non?small-cell lung carcinoma (NSCLC)

Bayer AG

Incorporated in 1863, Bayer AG is based in Leverkusen, Germany. It is a chemical and pharmaceutical company that markets products, helping prevent, diagnose, and treat diseases for humans and animals. The pharmaceutical division emphasizes on prescription products and specialty therapeutics in the areas of cardiology, women’s health, hematology, oncology, and ophthalmology.

F. Hoffmann-La Roche AG

Founded in 1896, F. Hoffmann-La Roche AG is headquartered in Basel, Switzerland. It is a global biopharmaceutical company engaged in the development, manufacture, and commercialization of pharmaceutical products and medical devices. Roche Pharmaceuticals is a world leader in biotechnology and oncology.

Novartis AG

Novartis AG founded in 1996 in Switzerland is a global health care company that develops, manufactures, and provides high-quality drugs and health care services. The company operates through three business segments: innovative medicines, Sandoz, and Alcon. The company’s innovative medicines business division operates through two units: Novartis Pharmaceuticals and Novartis Oncology. The Novartis Oncology unit develops therapeutic treatments in the fields of oncology and rare diseases.

Array BioPharma Inc.

The Array BioPharma Inc. is the U.S. based biopharmaceutical company founded in the year 1998. The company is primarily focused of clinical research, development and commercialization of targeted small molecules drugs against the treatment of cancer and high burden disorders.

BRAF Kinase Inhibitors Market Dynamics

High prevalence of non-small-cell lung carcinoma (NSCLC) is likely to be key contributing factor for the growth of BRAF Kinase Inhibitors Market.

The BRAF kinase inhibitors market is primarily driven by increase in the rate of incidence and prevalence of cancers such as metastatic melanoma and non-small-cell lung carcinoma (NSCLC). Melanoma is reported as the most common type of cancer worldwide with estimated, age-standardized incidence rates of 2.8–3.1 per 100,000 people. According to the American Cancer Society, about 96,480 new patients with melanomas would be diagnosed in the U.S. by the end of 2019. Out of these, about 39,260 would be women and 57,220 would be men. About 7,230 people are expected to die of melanoma. According to a study published in ‘Cancer.Net’, lung cancer is the second-most common cancer and it is a leading cause of cancer deaths among both men and women. Around 142,670 deaths are likely to be caused by lung cancer by the end of 2019. Non-small-cell lung carcinoma (NSCLC) is the most common type of lung cancer; it accounts for 84% of all lung cancer diagnoses.

Large number of clinical trial pipeline drugs and anticipated commercialization by various companies is one of the key driving factors during the forecast period.

The global BRAF kinase inhibitors market is expected to expand at a rapid pace during the forecast period. Research and development activities by key market players have increased over the last few years. They are focusing on extending the research on BRAF kinase inhibitors for other applications. Furthermore, several BRAF kinase inhibitor drugs are at the final stage of research and development and are expected to be launched during the forecast period.

BRAF Kinase Inhibitors Market – Segmentation